Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (13939)	1/30/1998 4:59:00 PM
From: Andrew H	Read Replies (2) \| Respond to of 32384

Henry, I would categorize the INHALE news as basically irrelevant since they are in no way in competition with LGND in regard to Targretin for diabetes. LGND has locked in its percentage of all Targretin for diabetes sales. Of course, INHL might be a great buy. But there is no effect on LGND. My guess is that current weakness is due to lack of leptin deal, too many shares outstanding and as you suggested and I have in the past, the likelihood that we will see further dilution soon when LGND declines the SRGN drug and takes the 20MM in equity. If the latter is the case, the weakness should already be in the stock. However, I must say I am not especially bullish on the stock price in the near term. As far as a list of upcoming news and milestones for the year, why don't we let the poster who suggested that do the work and see if he is actually capable of doing any meaningful DD on the company. Why do I doubt there will be any list?